JP7758355B2 - 設計された腫瘍溶解性アデノウイルス - Google Patents

設計された腫瘍溶解性アデノウイルス

Info

Publication number
JP7758355B2
JP7758355B2 JP2022560928A JP2022560928A JP7758355B2 JP 7758355 B2 JP7758355 B2 JP 7758355B2 JP 2022560928 A JP2022560928 A JP 2022560928A JP 2022560928 A JP2022560928 A JP 2022560928A JP 7758355 B2 JP7758355 B2 JP 7758355B2
Authority
JP
Japan
Prior art keywords
gene
virus
modified
modified virus
e3gp19k
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022560928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521076A (ja
JP2023521076A5 (https=
Inventor
ミン ユエン
Original Assignee
シェンチェン ホァ ヤオ カン ミン バイオファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェンチェン ホァ ヤオ カン ミン バイオファーマシューティカル カンパニー リミテッド filed Critical シェンチェン ホァ ヤオ カン ミン バイオファーマシューティカル カンパニー リミテッド
Publication of JP2023521076A publication Critical patent/JP2023521076A/ja
Publication of JP2023521076A5 publication Critical patent/JP2023521076A5/ja
Application granted granted Critical
Publication of JP7758355B2 publication Critical patent/JP7758355B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022560928A 2020-04-07 2021-04-07 設計された腫瘍溶解性アデノウイルス Active JP7758355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006115P 2020-04-07 2020-04-07
US63/006,115 2020-04-07
PCT/IB2021/052898 WO2021205364A1 (en) 2020-04-07 2021-04-07 Engineered oncolytic adenovirus

Publications (3)

Publication Number Publication Date
JP2023521076A JP2023521076A (ja) 2023-05-23
JP2023521076A5 JP2023521076A5 (https=) 2024-04-16
JP7758355B2 true JP7758355B2 (ja) 2025-10-22

Family

ID=78022983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560928A Active JP7758355B2 (ja) 2020-04-07 2021-04-07 設計された腫瘍溶解性アデノウイルス

Country Status (5)

Country Link
US (1) US20230149485A1 (https=)
EP (1) EP4133061A4 (https=)
JP (1) JP7758355B2 (https=)
CN (1) CN115605586B (https=)
WO (1) WO2021205364A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509197A (ja) 2011-03-02 2014-04-17 北京▲錘▼特生物科技有限公司 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用
JP2016522805A (ja) 2013-04-18 2016-08-04 ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 増強された養子細胞療法
WO2019158914A1 (en) 2018-02-16 2019-08-22 University College Cardiff Consultants Ltd Modified adenoviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
JP2021527694A (ja) * 2018-06-21 2021-10-14 レプリミュン リミテッド 腫瘍溶解性ウイルスを用いた処置
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509197A (ja) 2011-03-02 2014-04-17 北京▲錘▼特生物科技有限公司 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用
JP2016522805A (ja) 2013-04-18 2016-08-04 ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 増強された養子細胞療法
WO2019158914A1 (en) 2018-02-16 2019-08-22 University College Cardiff Consultants Ltd Modified adenoviruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Stella M. Y. K. et al.，The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells，Molecular Cancer Therapeutics，2018年，vol.17, no.2，p.575-587

Also Published As

Publication number Publication date
JP2023521076A (ja) 2023-05-23
CN115605586B (zh) 2024-09-06
US20230149485A1 (en) 2023-05-18
EP4133061A4 (en) 2024-05-29
WO2021205364A1 (en) 2021-10-14
EP4133061A1 (en) 2023-02-15
CN115605586A (zh) 2023-01-13

Similar Documents

Publication Publication Date Title
US20240100106A1 (en) Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers
JP7438552B2 (ja) 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用
US20180169271A1 (en) Armed replication-competent oncolytic adenoviruses
JP2021527694A (ja) 腫瘍溶解性ウイルスを用いた処置
JP7420751B2 (ja) Ｉ型インターフェロン及びｃｄ４０－配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
JP5042826B2 (ja) 腫瘍壊死因子関連アポトーシス誘導リガンド（ｔｒａｉｌ）を産生するように遺伝子操作された腫瘍帰巣細胞
JP7758355B2 (ja) 設計された腫瘍溶解性アデノウイルス
CN121319223B (zh) 一种靶向cd19和bcma的双特异性嵌合抗原受体及其相关产品和应用
WO2022170919A1 (zh) 一种重组溶瘤腺病毒及其应用
HK40101994A (zh) 改造的溶瘤病毒及其用途
WO2025031347A1 (zh) 肿瘤疫苗及其用途
CN120789239A (zh) 重组溶瘤病毒和单克隆抗体联用在制备用于治疗hbv阳性肝癌的药物中的应用
WO2007068487A2 (en) Tumour treatment with treg down-regulating active agents
HK40054249A (en) Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
HK40054249B (zh) 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗
HK1110874B (en) Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251002

R150 Certificate of patent or registration of utility model

Ref document number: 7758355

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150